Skip to content

US · PGEN · BIOTECHNOLOGY

Precigen, Inc. (PGEN) intrinsic value and stock valuation

$4.21as of 2026-11-21 · Mkt cap 2.46B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Precigen, Inc. DCF and intrinsic value

InvestorsCraft values PGEN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PGEN’s statements →

Precigen, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Germantown, MD 20876 precigen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$9.68M-21.3% 5y CAGRd
20112025
Net income
-$-250.64M
20112025
Free cash flow
-$-89.83M
20112025
Total equity
$20.9M-20.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$9.68M$3.92M$6.22M$26.9M$14.3M
Operating income-$-106.6M-$-135.03M-$-99.76M-$-75.73M-$-91.95M
Net income-$-250.64M-$-126.23M-$-95.9M$28.3M-$-92.17M
EPSd-$-822.55K-$-471.48K-$-392.16K$141.3K-$-466.07K
Operating cash flow-$-87.83M-$-68.17M-$-66.93M-$-65.05M-$-55.77M
Capital expenditure-$-2M-$-8.58M-$-1.54M-$-4.92M-$-7.25M
Free cash flow-$-89.83M-$-76.76M-$-68.47M-$-69.97M-$-63.02M
Total assets$156.6M$145.3M$151M$216M$359.9M
Total debt$98.3M$5.5M$7.1M$51.4M$190.1M
Net debt$68.1M-$-24.02M-$-480K$46.6M$153.7M
Total equity$20.9M$38.5M$118.5M$126.3M$107.4M
Cash and short-term investments$97.9M$97.9M$62.9M$56M$108.7M
Income statement
20252024202320222021
Revenue$9.68M$3.92M$6.22M$26.9M$14.3M
Cost of revenue$6.1M$4.27M$6.12M$6.34M$53.7M
Gross profit$3.59M-$-340K$110K$20.6M-$-39.41M
Research and development expenses$40.1M$53.1M$48.6M$47.2M$47.9M
Selling, general and administrative expenses$70.1M$41.3M$40.4M$48M$0.00
Other expenses$0.00$40.3M$10.8M$1.12M$4.6M
Operating expenses$110.2M$134.7M$99.9M$96.3M$52.5M
Cost and expenses$116.3M$139M$106M$102.6M$106.2M
Interest income$3.21M$1.42M$3.24M$130K$170K
Interest expense$3.87M$10K$470K$6.77M$18.8M
Depreciation and amortization$3.2M$4.53M$6.67M$10.8M$13.8M
Ebitda-$-243.57M-$-123.5M-$-89.23M-$-62.43M-$-77.64M
Operating income-$-106.6M-$-135.03M-$-99.76M-$-75.73M-$-91.95M
Total other income/expenses, net-$-144.04M$7M$3.4M-$-4.24M-$-19.02M
Income before tax-$-250.64M-$-128.03M-$-96.36M-$-79.97M-$-110.97M
Income tax expense$0.00-$-1.79M-$-460K-$-190K-$-160K
Net income-$-250.64M-$-126.23M-$-95.9M$28.3M-$-92.17M
Weighted average shares outstanding$304.7M$267.7M$244.5M$200.4M$197.8M
Weighted average diluted shares outstanding$304.7M$267.7M$244.5M$200.4M$197.8M
Balance sheet
20252024202320222021
Cash and short-term investments$97.9M$97.9M$62.9M$56M$108.7M
Net receivables$4.36M$1.16M$1.57M$13.8M$1.98M
Inventory$9.58M$0.00$0.00$290K$330K
Total current assets$115.2M$102.4M$68.8M$118.2M$156.6M
Property, plant and equipment, net$18.4M$18.8M$14.1M$15.3M$18.6M
Goodwill and intangible assets$18.4M$23.6M$67.3M$81.4M$89.8M
Long-term investments$2.51M$0.00$0.00$400K$48.6M
Total non-current assets$41.4M$42.9M$82.3M$97.8M$203.2M
Total assets$156.6M$145.3M$151M$216M$359.9M
Accounts payable$12M$3.53M$1.73M$4.07M$3.11M
Short-term debt$1.14M$960K$1.2M$44.4M$1.45M
Deferred revenue$520K$590K$510K$30K$1.49M
Total current liabilities$37.3M$21.5M$23M$78.6M$34.7M
Long-term debt$97.2M$4.55M$5.89M$6.99M$188.6M
Deferred revenue, non-current$0.00$1.93M$1.82M$1.82M$23M
Total non-current liabilities$98.4M$85.2M$9.56M$11.1M$217.9M
Capital lease obligations$5.12M$5.5M$7.1M$8.2M$10.1M
Total liabilities$135.7M$106.8M$32.6M$89.7M$252.5M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-2.34B-$-2.09B-$-1.96B-$-1.87B-$-1.92B
Accumulated other comprehensive income (loss)$10K$10K-$-1.95M-$-3.49M$200K
Total equity$20.9M$38.5M$118.5M$126.3M$107.4M
Total investments$70.1M$68.4M$55.3M$51.5M$120.8M
Total debt$98.3M$5.5M$7.1M$51.4M$190.1M
Net debt$68.1M-$-24.02M-$-480K$46.6M$153.7M
Cash flow statement
20252024202320222021
Net income-$-250.64M-$-126.23M-$-95.9M$28.3M-$-92.17M
Depreciation and amortization$3.2M$4.53M$6.67M$10.8M$13.8M
Stock-based compensation$10.9M$9.47M$9.89M$10.2M$13.9M
Change in working capital$6.62M$4.52M$17.1M-$-35.7M-$-800K
Accounts receivable-$-3.2M$410K$12.2M-$-13.51M-$-6.56M
Inventory-$-9.21M$0.00$0.00$2.34M-$-1.9M
Accounts payable$8.77M$1.55M-$-2.42M$380K$420K
Net cash provided by operating activities-$-87.83M-$-68.17M-$-66.93M-$-65.05M-$-55.77M
Investments in property, plant and equipment-$-2M-$-8.58M-$-1.54M-$-4.92M-$-7.25M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.53M-$-20.71M-$-3.09M$226.4M-$-74.54M
Common stock issued$310K$31.2M$72.8M$0.00$121.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$90.1M$110.6M$29.6M-$-155.29M$121.2M
Net change in cash$720K$21.7M-$-40.75M$5.25M-$-8.91M
Cash at end of period$30.2M$29.5M$7.85M$48.6M$43.3M
Operating cash flow-$-87.83M-$-68.17M-$-66.93M-$-65.05M-$-55.77M
Capital expenditure-$-2M-$-8.58M-$-1.54M-$-4.92M-$-7.25M
Free cash flow-$-89.83M-$-76.76M-$-68.47M-$-69.97M-$-63.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Precigen, Inc.

        Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

        CEO
        Helen Sabzevari
        Employees
        160
        Beta
        1.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Precigen, Inc. (PGEN)?

        Precigen, Inc. (PGEN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PGEN undervalued?

        PGEN trades at a price of $4.21 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.